

Doravirine Formulation

Version 5.1 Revision Date: 06/04/2018 SDS Number: 58388-00011 Date of last issue: 04/12/2018
 Date of first issue: 02/16/2015

SECTION 1. IDENTIFICATION

Product name : Doravirine Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
 Address : 2000 Galloping Hill Road
 Kenilworth - New Jersey - U.S.A. 07033
 Telephone : 908-740-4000
 Telefax : 908-735-1496
 Emergency telephone : 1-908-423-6000
 E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with 29 CFR 1910.1200

Combustible dust

GHS label elements

Signal Word : Warning
 Hazard Statements : If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.
 Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Hazardous ingredients

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 20 - < 30
Doravirine	1338225-97-0	>= 10 - < 20
Magnesium stearate	557-04-0	>= 1 - < 5
Silicon, amorphous	112945-52-5	>= 1 - < 5

SECTION 4. FIRST AID MEASURES

Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/12/2018
5.1	06/04/2018	58388-00011	Date of first issue: 02/16/2015

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately., When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.
- In case of skin contact : Wash with water and soap.
Get medical attention if symptoms occur.
- In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.
- Protection of first-aiders : No special precautions are necessary for first aid responders.
- Notes to physician : Treat symptomatically and supportively.
-

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Halogenated compounds
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.
Use personal protective equipment.

Doravirine Formulation

Version Revision Date: SDS Number: Date of last issue: 04/12/2018
5.1 06/04/2018 58388-00011 Date of first issue: 02/16/2015

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Follow safe handling advice and personal protective equipment recommendations.
- Environmental precautions : Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers. Store in accordance with the particular national regulations.
- Materials to avoid : No special restrictions on storage with other products.

Doravirine Formulation

Version 5.1 Revision Date: 06/04/2018 SDS Number: 58388-00011 Date of last issue: 04/12/2018
 Date of first issue: 02/16/2015

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
		TWA (Respirable)	5 mg/m ³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m ³	OSHA Z-1
Doravirine	1338225-97-0	TWA	0.1 mg/m ³ (OEB 2)	Internal
Magnesium stearate	557-04-0	TWA (Inhalable fraction)	10 mg/m ³	ACGIH
		TWA (Respirable fraction)	3 mg/m ³	ACGIH
Silicon, amorphous	112945-52-5	TWA (Dust)	20 Million particles per cubic foot (Silica)	OSHA Z-3
		TWA (Dust)	80 mg/m ³ / %SiO ₂ (Silica)	OSHA Z-3
		TWA	6 mg/m ³ (Silica)	NIOSH REL

Engineering measures : Use feasible engineering controls to minimize exposure to compound.
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection

Doravirine Formulation

Version 5.1 Revision Date: 06/04/2018 SDS Number: 58388-00011 Date of last issue: 04/12/2018
Date of first issue: 02/16/2015

- Material : Chemical-resistant gloves
- Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin and body protection : Work uniform or laboratory coat.
- Hygiene measures : Ensure that eye flushing systems and safety showers are located close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
-

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

- Appearance : powder
- Color : off-white
- Odor : No information available.
- Odor Threshold : No data available
- pH : No data available
- Melting point/freezing point : No data available
- Initial boiling point and boiling range : No data available
- Flash point : Not applicable
- Evaporation rate : Not applicable
- Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.
- Flammability (liquids) : No data available
- Upper explosion limit / Upper flammability limit : No data available
- Lower explosion limit / Lower flammability limit : No data available

Doravirine Formulation

Version 5.1 Revision Date: 06/04/2018 SDS Number: 58388-00011 Date of last issue: 04/12/2018
Date of first issue: 02/16/2015

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : None.

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Inhalation
Skin contact
Ingestion
Eye contact

Doravirine Formulation

Version 5.1 Revision Date: 06/04/2018 SDS Number: 58388-00011 Date of last issue: 04/12/2018
Date of first issue: 02/16/2015

Acute toxicity

Not classified based on available information.

Components:**Cellulose:**

- Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
- Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
- Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Assessment: The substance or mixture has no acute dermal toxicity

Doravirine:

- Acute oral toxicity : LD50 (Rat): > 750 mg/kg
Remarks: No mortality observed at this dose.
- (Rat): 450 mg/kg/day
Method: Phototoxicity
Remarks: No evidence of phototoxicity was observed
- LD50 (Dog): > 1,000 mg/kg
Remarks: No mortality observed at this dose.
- LD50 (Mouse): > 450 mg/kg
Remarks: No mortality observed at this dose.

Magnesium stearate:

- Acute oral toxicity : LD50 (Rat): > 2,500 mg/kg
Assessment: The substance or mixture has no acute oral toxicity

Silicon, amorphous:

- Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Method: OECD Test Guideline 401
Remarks: Based on data from similar materials
- Acute inhalation toxicity : LC50 (Rat): > 2.08 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Assessment: The substance or mixture has no acute inhalation toxicity
Remarks: Based on data from similar materials
- Acute dermal toxicity : LD50 (Rabbit): > 5,000 mg/kg
Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Doravirine Formulation

Version 5.1 Revision Date: 06/04/2018 SDS Number: 58388-00011 Date of last issue: 04/12/2018
Date of first issue: 02/16/2015

Components:**Cellulose:**

Result : No skin irritation
Remarks : Based on data from similar materials

Doravirine:

Remarks : No data available

Silicon, amorphous:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation
Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Cellulose:**

Result : No eye irritation
Remarks : Based on data from similar materials

Doravirine:

Remarks : No data available

Silicon, amorphous:

Species : Rabbit
Result : No eye irritation
Method : OECD Test Guideline 405
Remarks : Based on data from similar materials

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**Cellulose:**

Test Type : Local lymph node assay (LLNA)
Routes of exposure : Skin contact
Species : Mouse
Method : OECD Test Guideline 429
Result : negative
Remarks : Based on data from similar materials

Doravirine Formulation

Version 5.1 Revision Date: 06/04/2018 SDS Number: 58388-00011 Date of last issue: 04/12/2018
Date of first issue: 02/16/2015

Doravirine:

Remarks : No data available

Magnesium stearate:

Routes of exposure : Skin contact
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:**Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

Doravirine:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Rat
Cell type: Bone marrow
Application Route: Oral
Result: negative

Silicon, amorphous:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative
Remarks: Based on data from similar materials

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

Doravirine Formulation

Version 5.1 Revision Date: 06/04/2018 SDS Number: 58388-00011 Date of last issue: 04/12/2018
 Date of first issue: 02/16/2015

Carcinogenicity

Not classified based on available information.

Components:**Doravirine:**

Species : Mouse
 Application Route : Oral
 Exposure time : 6 Months
 Result : negative
 Remarks : No significant adverse effects were reported

Silicon, amorphous:

Species : Rat
 Application Route : Ingestion
 Exposure time : 103 weeks
 Result : negative
 Remarks : Based on data from similar materials

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Components:**Doravirine:**

Effects on fertility : Test Type: Fertility
 Species: Rat, male and female
 Fertility: NOAEL: 450 mg/kg body weight
 Result: No effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development
 Species: Rat
 Application Route: Oral
 Developmental Toxicity: NOAEL: 450 mg/kg body weight
 Result: No adverse effects.

Test Type: Embryo-fetal development
 Species: Rabbit
 Application Route: Oral
 Developmental Toxicity: NOAEL: 450 mg/kg body weight
 Result: No adverse effects.

Silicon, amorphous:

Effects on fetal development : Test Type: Embryo-fetal development

Doravirine Formulation

Version 5.1 Revision Date: 06/04/2018 SDS Number: 58388-00011 Date of last issue: 04/12/2018
Date of first issue: 02/16/2015

Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Repeated dose toxicity**Components:****Cellulose:**

Species : Rat
NOAEL : > 5,000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days
Remarks : Based on data from similar materials

Doravirine:

Species : Rat
NOAEL : 450 mg/kg
Application Route : Oral
Exposure time : 6 Months
Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : > 450 mg/kg
Application Route : Oral
Exposure time : 3 Months
Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : > 1,000 mg/kg
Application Route : Oral
Exposure time : 9 Months
Remarks : No significant adverse effects were reported

Magnesium stearate:

Species : Rat
NOAEL : 5,000 mg/kg
Application Route : Ingestion
Exposure time : 3 Months

Silicon, amorphous:

Species : Rat
NOAEL : 1.3 mg/l
Application Route : inhalation (dust/mist/fume)
Exposure time : 13 Weeks
Remarks : Based on data from similar materials

Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/12/2018
5.1	06/04/2018	58388-00011	Date of first issue: 02/16/2015

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Doravirine:**

Ingestion : Symptoms: confusion, Headache, Dizziness, Nausea, Rash, abnormal dreams, flushing

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Cellulose:**

Toxicity to fish : LC50 (Cyprinus carpio (Carp)): > 100 mg/l
 Exposure time: 96 h
 Method: OECD Test Guideline 203
 Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
 Exposure time: 48 h
 Method: OECD Test Guideline 202
 Remarks: Based on data from similar materials

Toxicity to algae : EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 201
 Remarks: Based on data from similar materials

Doravirine:

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 39 mg/l
 Exposure time: 48 h
 Method: OECD Test Guideline 202
 Remarks: No toxicity at the limit of solubility.

EC50 (Americamysis): 9.1 mg/l
 Exposure time: 96 h

Toxicity to algae : EC50 (Pseudokirchneriella subcapitata (green algae)): > 5.8 mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 221
 Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 5.8 mg/l
 Exposure time: 72 h

Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/12/2018
5.1	06/04/2018	58388-00011	Date of first issue: 02/16/2015

Method: OECD Test Guideline 221
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 1 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 6.7 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Silicon, amorphous:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 10,000 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 1,000 mg/l
Exposure time: 24 h
Method: OECD Test Guideline 202
Remarks: Based on data from similar materials

Toxicity to algae : EC50 (Desmodesmus subspicatus (green algae)): > 10,000 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

NOEC (Desmodesmus subspicatus (green algae)): 10,000 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Persistence and degradability**Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

Doravirine:

Doravirine Formulation

Version 5.1 Revision Date: 06/04/2018 SDS Number: 58388-00011 Date of last issue: 04/12/2018
Date of first issue: 02/16/2015

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 2 %
Exposure time: 28 d

Magnesium stearate:

Biodegradability : Result: Not biodegradable.

Bioaccumulative potential**Components:****Doravirine:**

Partition coefficient: n-octanol/water : log Pow: 2.08

Mobility in soil**Components:****Doravirine:**

Distribution among environmental compartments : log Koc: 2.86

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/12/2018
5.1	06/04/2018	58388-00011	Date of first issue: 02/16/2015

49 CFR

Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION**EPCRA - Emergency Planning and Community Right-to-Know****CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Combustible dust**SARA 313** : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.**US State Regulations****Pennsylvania Right To Know**

Cellulose, 2-hydroxypropyl methyl ether, acetate hydrogen butanedioate	71138-97-1
Cellulose	9004-34-6
D-Glucose, 4-O-.beta.-D-galactopyranosyl-, monohydrate	64044-51-5
Doravirine	1338225-97-0
Croscarmellose sodium	74811-65-7
Silicon, amorphous	112945-52-5

California Prop. 65

This product does not contain any chemicals known to the State of California to cause cancer, birth, or any other reproductive defects.

California Permissible Exposure Limits for Chemical Contaminants

Cellulose	9004-34-6
Magnesium stearate	557-04-0
Silicon, amorphous	112945-52-5

The ingredients of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined


Doravirine Formulation

Version 5.1 Revision Date: 06/04/2018 SDS Number: 58388-00011 Date of last issue: 04/12/2018
 Date of first issue: 02/16/2015

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:



HMIS® IV:

HEALTH	/	0
FLAMMABILITY	3	
PHYSICAL HAZARD	0	

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
OSHA Z-3	:	USA. Occupational Exposure Limits (OSHA) - Table Z-3 Mineral Dusts
ACGIH / TWA	:	8-hour, time-weighted average
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA Z-1 / TWA	:	8-hour time weighted average
OSHA Z-3 / TWA	:	8-hour time weighted average

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); EC_x - Concentration associated with x% response; EHS - Extremely Hazardous Substance; EL_x - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErC_x - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC₅₀ - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC₅₀ - Lethal Concentration to 50 % of a test population; LD₅₀ - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable

Doravirine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/12/2018
5.1	06/04/2018	58388-00011	Date of first issue: 02/16/2015

Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 06/04/2018

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8